VivoSeq
Ophthalmology

Uveitic Macular Edema

0

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Uveitic Macular Edema is an early-stage landscape with 0 programs across 1 company. The most active players are Roche.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

56/100

Attrition Rate

44/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

9

clinical trials

Completed5 · 56%
Withdrawn2 · 22%
Terminated2 · 22%

Clinical Trials

Trial Activity

9 trials

PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial
Completed·JJHSPH Center for Clinical Trials·Phase 3·NCT02374060·192 enrolled
A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema
Completed·Roche logoRoche·Phase 1·NCT06771271·85 enrolled
A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema
Completed·Roche logoRoche·Phase 3·NCT05642312·245 enrolled
Vamikibart in Participants With Uveitic Macular Edema
Completed·Roche logoRoche·Phase 3·NCT05642325·256 enrolled
TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema
Completed·NNorthern California Retina Vitreous Associates·Phase 4·NCT01870440·10 enrolled
Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema
Terminated·National Institutes of Health Clinical Center (CC)·Phase 1/2·NCT01194674·2 enrolled
Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF
Terminated·PPeking Union Medical College Hospital·Phase 2/3·NCT04296838·5 enrolled
Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids
Withdrawn·UUniversity of Utah·Phase 2·NCT00846625
Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema
Withdrawn·IIcahn School of Medicine at Mount Sinai·Phase 1/2·NCT00958906·10 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)